News

Lonza announces the addition of two new Ibex Solutions offerings to Lonza's 100,000 m2 (1.1 million ft2) biopark in Visp (CH). In July 2017 Ibex Dedicate, a modular, technology-agnostic…
Read More...

Thermo Fisher Scientific announced its intent to open multiple Global Customer Solution Centers. The new Global Customer Solution Centers will focus on meeting and exceeding the demands…
Read More...

Emergex Vaccines Holding Limited announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral…
Read More...

Cardurion Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733, a Phosphodiesterase-9…
Read More...

Aphena Pharma Solutions Inc. has expanded its DEA operations and storage in both its Maryland and Tennessee manufacturing locations. Aphena's liquid and semisolids division in Easton,…
Read More...

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer,…
Read More...

Zosano Pharma Corporation announced the release of three registration batches of M207, the Company’s lead development candidate. The registration batches will be used to support…
Read More...

Molecular Templates announced an agreement with Takeda Pharmaceutical Company Limited (Takeda) for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the…
Read More...

Abzena has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen…
Read More...

Propanc Biopharma announced the execution of a research collaboration agreement with the University of Jaén, Spain, for the provision of research services and scientific technical…
Read More...

Adverum Biotechnologies announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ADVM-022. ADVM-022 is a novel gene therapy candidate for the…
Read More...

AstraZeneca announced results from the BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in…
Read More...

Just Biotherapeutics and Pandion Therapeutics announced that they have entered into an agreement for the development and cGMP clinical manufacturing by Just of Pandion’s lead program.…
Read More...

Valeo Pharma and Besins Healthcare announced a strategic agreement to commercialize Utrogestan (micronised natural progesterone; 200mg vaginal capsules) in Canada. Utrogestan is…
Read More...

Atomwise Inc. has entered into an evaluation agreement with Pfizer. Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins…
Read More...

Roivant Sciences announced the launch of Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases.…
Read More...

Evotec AG and Almirall announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics through a novel approach to disrupt cell…
Read More...

Avista Pharma Solutions has announced upgrades to its Agawam, MA facility, increasing its analytical chemistry footprint while expanding its compendial and raw material testing…
Read More...

Halozyme Therapeutics announced that Roche has received approval from Health Canada for a subcutaneous (SC) formulation of trastuzumab (Herceptin SC) for the treatment of patients with…
Read More...

Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation for North American rights to Samumed's SM04646, being developed for the treatment of…
Read More...